Vaccines, Biologics: Indian Pharma’s New Temptations
API, diagnostics, New Chemical Entity — Covid has thrown up new opportunities, and domestic pharma biggies are charging in with renewed focus.
biologics
February 2022
October 2019
Biocon’s biologics portfolio comes into its own
Bengaluru-based Biocon’s portfolio of biologic drugs has grown rapidly in the last five years and the company wants it to be a $1 billion business by 2022.
